JO3669B1 - بيبتيدات مضَادَّة لببتيد المرتبط بجين الكالسيتونين - Google Patents

بيبتيدات مضَادَّة لببتيد المرتبط بجين الكالسيتونين

Info

Publication number
JO3669B1
JO3669B1 JOP/2016/0002A JOP20160002A JO3669B1 JO 3669 B1 JO3669 B1 JO 3669B1 JO P20160002 A JOP20160002 A JO P20160002A JO 3669 B1 JO3669 B1 JO 3669B1
Authority
JO
Jordan
Prior art keywords
cgrp antagonist
antagonist peptides
compounds
formula
peptides
Prior art date
Application number
JOP/2016/0002A
Other languages
English (en)
Inventor
J Sueiras-Diaz Javier
Jiang Guangcheng
K Rabinovich Aleksandr
Wisniewski Kazimierz
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Application granted granted Critical
Publication of JO3669B1 publication Critical patent/JO3669B1/ar

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64Cyclic peptides containing only normal peptide links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)

Abstract

-<span dir="RTL">يتعلق الإفصاح بمركبات من الصيغة (</span>I<span dir="RTL">) أو ملح منه مقبول دوائيا التي فيه </span>m<span dir="RTL"> و </span>p<span dir="RTL"> و </span>A<span dir="RTL"> و </span>Ar1<span dir="RTL"> و </span>Ar2<span dir="RTL"> و </span>Ar3<span dir="RTL"> و </span>R1<span dir="RTL"> و </span>R3<span dir="RTL"> و يتم تحديده في الوصف. يمكن أن تستخدم المركبات من الصيغة (</span>I<span dir="RTL">) حيث يمكن استخدام مثبطات الببتيد المرتبط بجين الكالسيتونين لعلاج الصداع النصفي.</span>
JOP/2016/0002A 2015-01-06 2016-01-04 بيبتيدات مضَادَّة لببتيد المرتبط بجين الكالسيتونين JO3669B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562100371P 2015-01-06 2015-01-06

Publications (1)

Publication Number Publication Date
JO3669B1 true JO3669B1 (ar) 2020-08-27

Family

ID=55071041

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2016/0002A JO3669B1 (ar) 2015-01-06 2016-01-04 بيبتيدات مضَادَّة لببتيد المرتبط بجين الكالسيتونين

Country Status (34)

Country Link
US (1) US9969775B2 (ar)
EP (1) EP3242882B1 (ar)
JP (1) JP6929227B2 (ar)
KR (1) KR102713739B1 (ar)
CN (1) CN107207567B (ar)
AR (1) AR103499A1 (ar)
AU (1) AU2016206059B2 (ar)
BR (1) BR112017013413A2 (ar)
CA (1) CA2973041A1 (ar)
CL (1) CL2017001761A1 (ar)
CO (1) CO2017007940A2 (ar)
DK (1) DK3242882T3 (ar)
EA (1) EA032082B1 (ar)
ES (1) ES2924410T3 (ar)
HR (1) HRP20220941T1 (ar)
HU (1) HUE059379T2 (ar)
IL (1) IL252903B (ar)
JO (1) JO3669B1 (ar)
LT (1) LT3242882T (ar)
MA (1) MA41311B1 (ar)
MD (1) MD3242882T2 (ar)
MX (1) MX387920B (ar)
MY (1) MY196439A (ar)
PH (1) PH12017501214A1 (ar)
PL (1) PL3242882T3 (ar)
PT (1) PT3242882T (ar)
RS (1) RS63467B1 (ar)
SA (1) SA517381865B1 (ar)
SG (1) SG11201705306UA (ar)
SI (1) SI3242882T1 (ar)
TN (1) TN2017000248A1 (ar)
TW (1) TWI717331B (ar)
UA (1) UA121490C2 (ar)
WO (1) WO2016110499A1 (ar)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018362018A1 (en) * 2017-11-06 2020-06-25 Auckland Uniservices Limited Peptide conjugate CGRP receptor antagonists and methods of preparation and uses thereof
WO2025202938A1 (en) 2024-03-26 2025-10-02 Nuvie Bio, Inc. Pharmaceutical composition comprising a cgrp receptor antagonist for the treatment of acute migraine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268474B1 (en) * 1998-04-30 2001-07-31 Creighton University Peptide antagonists of CGRP-receptor superfamily and methods of use
TW200533398A (en) 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
US20060004185A1 (en) * 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
CA2582593A1 (en) * 2004-10-07 2006-04-20 Merck & Co., Inc. Cgrp receptor antagonists
EP1838725A1 (en) * 2005-01-17 2007-10-03 Jerini AG C5a receptor antagonists
CN101208303A (zh) * 2005-03-14 2008-06-25 默克公司 Cgrp受体拮抗剂
US8168592B2 (en) * 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
RS20080200A (en) * 2005-11-14 2009-07-15 Rinat Neuroscience Corp., Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
ZA200810791B (en) * 2006-06-13 2010-03-31 Vertex Pharma CGRP receptor antagonists
WO2013112912A1 (en) 2012-01-26 2013-08-01 Soares Christopher J Peptide antagonists of the calcitonin cgrp family of peptide hormones and their use

Also Published As

Publication number Publication date
MA41311A (fr) 2017-11-14
SA517381865B1 (ar) 2021-09-15
EA201791456A1 (ru) 2018-01-31
JP2018505213A (ja) 2018-02-22
LT3242882T (lt) 2022-08-25
PL3242882T3 (pl) 2022-10-31
PH12017501214A1 (en) 2018-01-08
SG11201705306UA (en) 2017-07-28
JP6929227B2 (ja) 2021-09-01
EA032082B1 (ru) 2019-04-30
UA121490C2 (uk) 2020-06-10
DK3242882T3 (en) 2022-08-08
CA2973041A1 (en) 2016-07-14
ES2924410T3 (es) 2022-10-06
US20180002378A1 (en) 2018-01-04
AR103499A1 (es) 2017-05-17
KR20170102302A (ko) 2017-09-08
KR102713739B1 (ko) 2024-10-04
IL252903B (en) 2021-01-31
BR112017013413A2 (pt) 2018-01-09
NZ732771A (en) 2024-07-05
MD3242882T2 (ro) 2022-10-31
CN107207567A (zh) 2017-09-26
CO2017007940A2 (es) 2017-10-31
HUE059379T2 (hu) 2022-11-28
TW201630929A (zh) 2016-09-01
AU2016206059A1 (en) 2017-07-20
MA41311B1 (fr) 2022-10-31
CN107207567B (zh) 2021-11-23
MX2017008893A (es) 2017-10-25
AU2016206059B2 (en) 2019-07-25
EP3242882B1 (en) 2022-05-04
US9969775B2 (en) 2018-05-15
EP3242882A1 (en) 2017-11-15
PT3242882T (pt) 2022-08-09
MX387920B (es) 2025-03-19
SI3242882T1 (sl) 2022-09-30
CL2017001761A1 (es) 2018-01-26
TWI717331B (zh) 2021-02-01
RS63467B1 (sr) 2022-08-31
IL252903A0 (en) 2017-08-31
WO2016110499A1 (en) 2016-07-14
HRP20220941T1 (hr) 2022-10-28
TN2017000248A1 (en) 2018-10-19
MY196439A (en) 2023-04-11

Similar Documents

Publication Publication Date Title
PH12017502107A1 (en) Triazole agonists of the apj receptor
EA201892710A1 (ru) Карбамоилоксиметилтриазолциклогексильные кислоты в качестве антагонистов lpa
MX384087B (es) Piperidinas como inhibidores de menina.
TN2018000276A1 (en) Inhibitors of receptor-interacting protein kinase 1.
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
TN2017000544A1 (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
PH12016501972B1 (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
MD20170016A2 (ro) Compuşi aminopirimidinici ca inhibitori JAK
PH12018500408A1 (en) Bicyclic compounds as atx inhibitors
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
EA201691913A1 (ru) Замещенные [1,2,4]триазольные и имидазольные соединения в качестве фунгицидов
PH12018500409A1 (en) New bicyclic compounds as dual atx/ca inhibitors
EA201591420A1 (ru) Гетероарильные соединения и их применение
EA201692526A1 (ru) Замещенные [1,2,4]триазольные соединения
PH12017502051A1 (en) TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF
CL2015002897A1 (es) Inhibidores de bace1
NZ725165A (en) Analogues of 4h-pyrazolo[1,5-α]benzimidazole compound as parp inhibitors
MX390051B (es) Antagonistas de ep4.
EA201692474A1 (ru) Производные 1-(циклопент-2-ен-1-ил)-3-(2-гидрокси-3-(арилсульфонил)фенил)мочевины в качестве ингибиторов cxcr2
EA201692289A1 (ru) Замещенные [1,2,4]триазольные и имидазольные соединения в качестве фунгицидов
NZ738990A (en) Cgrp receptor antagonists
EA201700356A1 (ru) Новые циклопропанбензофуранилпиридопиразиндионы
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
EA201791099A1 (ru) Хинолин карбоксамиды для применения в лечении лейкоза
PH12017501214A1 (en) Cgrp antagonist peptides